Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.

CONTEXT Controversy surrounds the diagnostic and prognostic importance of slightly elevated cardiac markers in patients with acute coronary syndromes without ST-segment elevation. OBJECTIVES To investigate the relationship between peak creatine kinase (CK)-MB level and outcome and to determine whether a threshold CK-MB level exists below which risk is not increased. DESIGN AND SETTING Retrospective observational analysis of data from the international Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, conducted from November 1995 to January 1997. PATIENTS A total of 8250 patients with acute coronary syndromes without ST-segment elevation who had at least 1 CK-MB sample collected during their index hospitalization. MAIN OUTCOME MEASURE Mortality at 30 days and 6 months, was assessed by category of index-hospitalization peak CK-MB level (0-1, >1-2, >2-3, >3-5, >5-10, or >10 times the upper limit of normal). Multivariable logistic regression was used to determine the independent prognostic significance of peak CK-MB level after adjustment for baseline predictors of 30-day and 6-month mortality. RESULTS Mortality at 30 days and 6 months increased from 1.8% and 4.0%, respectively, in patients with normal peak CK-MB levels, to 3.3% and 6.2 % at peak CK-MB levels 1 to 2 times normal, to 5.1% and 7.5% at peak CK-MB levels 3 to 5 times normal, and to 8.3% and 11.0% at peak CK-MB levels greater than 10 times normal. Log-transformed peak CK-MB levels were predictive of adjusted 30-day and 6-month mortality (P<.001 for both). CONCLUSIONS Our data show that elevation of CK-MB level is strongly related to mortality in patients with acute coronary syndromes without ST-segment elevation, and that the increased risk begins with CK-MB levels just above normal. In the appropriate clinical context, even minor CK-MB elevations should be considered indicative of myocardial infarction.

[1]  W. Rogers,et al.  Correlation of Angiographic Estimates of Myocardial Infarct Size and Accumulated Release of Creatine Kinase MB Isoenzyme in Man , 1977, Circulation.

[2]  L. Medeiros,et al.  The prognostic significance of immunoradiometric CK-MB assay (IRMA) diagnosis of myocardial infarction in patients with low total CK and elevated MB isoenzymes. , 1989, American heart journal.

[3]  R. W. Brower,et al.  Prognosis of patients with different peak serum creatine kinase levels after first myocardial infarction. , 1985, European heart journal.

[4]  G. Wagner.  Optimal use of serum enzyme levels in the diagnosis of acute myocardial infarction. The perspective in 1980. , 1980, Archives of internal medicine.

[5]  M. Simoons.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.

[6]  U. Goldbourt,et al.  Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction , 1993 .

[7]  C. W. Small,et al.  Clinical measurement of myocardial infarct size. Modification of a method for the estimation of total creatine phosphokinase release after myocardial infarction. , 1975, Circulation.

[8]  M. Weisfeldt,et al.  Creatine kinase of heart mitochondria. The progressive loss of enzyme activity during in vivo ischemia and its correlation to depressed myocardial function. , 1985, The Journal of biological chemistry.

[9]  B. Sobel,et al.  Biochemical markers of ischemic injury. , 1976, Circulation.

[10]  David Oakes,et al.  Prognostic significance of nonfatal myocardial reinfarction , 1990 .

[11]  E W Steyerberg,et al.  Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. , 2000, Circulation.

[12]  D. Mercer,et al.  Detection of cardiac-specific creatine kinase isoenzyme in sera with normal or slightly increased total creatine kinase activity. , 1975, Clinical chemistry.

[13]  R. Bonow,et al.  Prognostic implication of creatine kinase elevation following elective coronary artery interventions. , 1997, JAMA.

[14]  S. Effert,et al.  Infarct Size Estimated from Serial Serum Creatine Phosphokinase in Relation to Left Ventricular Hemodynamics , 1977, Circulation.

[15]  E. Braunwald,et al.  Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators. , 1995, Journal of the American College of Cardiology.

[16]  E. Topol,et al.  Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. , 1996, Circulation.

[17]  D Wybenga,et al.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. , 1996, The New England journal of medicine.

[18]  G. Schulz,et al.  Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. , 1999, Journal of the American College of Cardiology.

[19]  R. Califf,et al.  Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). , 1995, Journal of the American College of Cardiology.

[20]  B. Sobel,et al.  Estimation of Infarct Size in Man and its Relation to Prognosis , 1972, Circulation.

[21]  C. Heeschen,et al.  Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. , 1999, The New England journal of medicine.

[22]  Sobel Be,et al.  Biochemical markers of ischemic injury. , 1976 .

[23]  F. Harrell,et al.  Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia , 1996 .

[24]  R. Collins,et al.  Significance of elevated MB isoenzyme with normal creatine kinase in acute myocardial infarction. , 1987, The American journal of cardiology.

[25]  J. Wei,et al.  Elevated CK-MB with normal total creatine kinase in suspected myocardial infarction: associated clinical findings and early prognosis. , 1986, American heart journal.

[26]  Ric,et al.  CARDIAC TROPONIN T LEVELS FOR RISK STRATIFICATION IN ACUTE MYOCARDIAL ISCHEMIA , 2000 .

[27]  J. Deckers,et al.  Prognostic significance of nonfatal myocardial reinfarction in survivors of a first infarction. , 2001, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[28]  A. Jaffe,et al.  Biochemical Markers of Myocardial Injury Is MB Creatine Kinase the Choice for the 1990s? , 1993, Circulation.

[29]  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. , 1998, The New England journal of medicine.

[30]  S. Effert,et al.  Attempt to quantitate relation between cardiac function and infarct size in acute myocardial infarction. , 1974, British heart journal.

[31]  oldmann,et al.  EMERGENCY ROOM TRIAGE OF PATIENTS WITH ACUTE CHEST PAIN BY MEANS OF RAPID TESTING FOR CARDIAC TROPONIN T OR TROPONIN I , 2000 .

[32]  R. Califf,et al.  Myonecrosis after revascularization procedures. , 1998, Journal of the American College of Cardiology.

[33]  R. Califf,et al.  Minimal myocardial damage during coronary intervention is associated with impaired outcome. , 1999, European heart journal.

[34]  M. Harbinson,et al.  Periprocedural creatine kinase‐mb elevations: Long‐term impact and clinical implications , 1999, Clinical cardiology.

[35]  J. R. Cox,et al.  Relation between infarct size and ventricular arrhythmia. , 1975, British heart journal.

[36]  R. Califf,et al.  Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention , 1999 .

[37]  David P Miller,et al.  Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. , 1998, Circulation.

[38]  J. R. Cox,et al.  Relations between enzymatically estimated myocardial infarct size and early ventricular dysrhythmia. , 1976, Circulation.

[39]  E. Grenadier,et al.  THE MB ISOENZYME OF CREATINE KINASE AS AN INDICATOR OF SEVERITY OF MYOCARDIAL ISCHÆMIA , 1978, The Lancet.

[40]  R. Califf,et al.  Diagnostic and prognostic significance of minimally elevated creatine kinase-MB in suspected acute myocardial infarction. , 1985, The American journal of cardiology.

[41]  R. E. Clark,et al.  The Association of Increased Plasma MB CPK Activity and Irreversible Ischemic Myocardial Injury in the Dog , 1976, Circulation.